Trial Summary
What is the purpose of this trial?
Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes unrecognized and under-managed in people with CF. Both medication and non-medication interventions can be used to treat pain and ideally, there is a multicomponent management approach. The goal of this study is to pilot a new 3-session non-medication mind-body pain management intervention specifically designed for adults with cystic fibrosis (CF). The intervention is titled Pain Acknowledgement Coping and Empowerment in CF (PACE CF). PACE CF will be administered by a member of the CF care team via telehealth visits to participants at home or during a hospitalization. The aim of the study is to evaluate the feasibility and patient acceptability of the intervention as well as preliminary evidence of the impact of the intervention on pain and its interference in daily life. The study will also examine outcomes such as perceived coping, quality of life, symptoms of depression or anxiety, and use of prescribed pain medication, in an exploratory manner.
Will I have to stop taking my current medications?
The trial does not require you to stop taking your current medications. In fact, it encourages a multi-component approach to pain management, which can include your existing pain medications.
What data supports the effectiveness of the treatment Pain Acknowledgment Coping and Empowerment in CF (PACE CF) for managing pain in cystic fibrosis?
The research highlights the importance of patient empowerment in managing the high treatment burden of cystic fibrosis, suggesting that empowering patients can be beneficial. Additionally, clinicians see value in non-drug approaches for symptom management, which aligns with the goals of PACE CF.12345
How is the PACE CF treatment different from other treatments for cystic fibrosis?
Research Team
Amanda Bruce, PhD
Principal Investigator
University of Kansas Medical Center
Eligibility Criteria
This trial is for adults with cystic fibrosis who experience pain. Participants must be able to attend three telehealth sessions and may be at home or hospitalized. Specific eligibility criteria are not provided, but typically include factors like age range, disease severity, and ability to comply with study requirements.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants complete a 3-session mind-body pain management program (PACE CF) via telehealth
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of quality of life and pain management
Treatment Details
Interventions
- Pain Acknowledgment Coping and Empowerment in CF (PACE CF) (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Dr. William Curry
Massachusetts General Hospital
Chief Medical Officer
MD from Harvard Medical School
Dr. Anne Klibanski
Massachusetts General Hospital
Chief Executive Officer since 2019
MD from Harvard Medical School
University of Kansas Medical Center
Collaborator
Dr. Steve Stites
University of Kansas Medical Center
Chief Executive Officer
MD from University of Kansas School of Medicine
Dr. Matthias Salathe
University of Kansas Medical Center
Chief Medical Officer
MD from University of Kansas School of Medicine